Table 3.

Ongoing genetically engineered TCR T-cell therapies in progress.

NCT number	Phase	Target	Planned enrolment	Patient population	HLA class (if stated)	Sponsor	Region/country	Primary outcome	Status
4745403	l	HBV Ag	10	HBV Ag + advanced HCC	HLA-A∗02:01 or HLA-A∗24:02	Lion TCR Pte. Ltd.	Singapore	Safety	Recruiting
3899415	l	HBV Ag	10	HBV Ag + advanced HCC		Beijing 302 Hospital	China	Safety	Recruiting
4677088	l	HBV Ag	7	HBV Ag+ HCC post- transplant		Xiaoshun He	China	Safety	Unknown
2686372	l	HBV Ag	13	HBV Ag+ HCC post -transplant		Lion TCR Pte. Ltd	China	Adverse events	Completed
5339321	l	HBV Ag	36	HBV Ag + advanced HCC	HLA-A∗02:01	Peking Union Medical College Hospital	China	Adverse events	Unknown
5195294	l/ll	HBV Ag	55	HBV Ag + advanced HCC		Lion TCR Pte. Ltd	NR	Adverse events	Not recruiting
5417932	l/lla	HBV Ag	46	HBV Ag + advanced HCC	HLA-A∗02:01	SCG Cell Therapy Pte. Ltd	Hong Kong, Singapore, USA	Safety and response	Recruiting
3971747	l	AFP	9	HCC serum AFP >200 ng/ml	HLA-A∗02:01	Cellular Biomedicine Group Ltd.	China	Adverse events	Unknown
4368182	l	AFP	3	HCC serum AFP >200 ng/ml	HLA-A∗02:01	Zhejiang University	China	Safety	Unknown
3132792	l	AFP	30	HCC serum AFP ≥100 ng/ml	HLA-A∗02:01	Adaptimmune	EU and USA	DLT and adverse events	Completed

AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.